Clinical Trial: Acalabrutinib in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional
Official Title: A Phase 1b Study of ACP-196 in Combination With Obinutuzumab for Patients With Relapsed / Refractory or Untreated CLL/SLL/PLL
Brief Summary: To evaluate the safety and preliminary efficacy of acalabrutinib in combination with obinutuzumab in 2 separate cohorts of patients.
Detailed Summary:
Sponsor: Acerta Pharma BV
Current Primary Outcome: The overall response rate (ORR) at 12 months with the combination of acalabrutinib + obinutuzumab in patients [ Time Frame: 12 Months ]
Original Primary Outcome: The overall response rate (ORR) at 12 months with the combination of ACP-196 + obinutuzumab in patients [ Time Frame: 12 Months ]
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Acerta Pharma BV
Dates:
Date Received: November 19, 2014
Date Started: November 2014
Date Completion:
Last Updated: December 2, 2016
Last Verified: December 2016